RxDoctor Payments Data

Peter Engel, MD

Cardiovascular Disease · Cincinnati, OHNPI 1447237342

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Bayer accounts for 75.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $5,609 and has fallen 85.2% since, to $831 in 2025.

$11,044in general payments, 2019–2025

Across 109 payments — averaging $101.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$8K
  • Actelion Pharmaceuticals US, Inc.$1K
  • United Therapeutics Corporation$611
  • Merck$380
  • Sandoz$153
  • Tosoh Bioscience, Inc.$95
  • plus $166 from 5 others
$1,141,857in research payments, 2019–2025

Across 112 payments — averaging $10,195 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$907K
  • Actelion Pharmaceuticals, Ltd$83K
  • Janssen Research & Development, LLC$81K
  • United Therapeutics Corporation$71K

What the payments were for

  • Consulting fees$2,87526%
  • Speaking & faculty fees$5,04046%
  • Food & beverage$2,97127%
  • Education$621%
  • Gifts$951%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,044 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$74,127
Medicare patients
222
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan305$3,831,301
UptraviSelexipag152$3,105,120
AdempasRiociguat90$1,241,815
Ambrisentan49$239,843
EliquisApixaban132$121,260
Bosentan48$95,280
Tadalafil183$93,115
XareltoRivaroxaban65$73,742
EntrestoSacubitril/Valsartan62$55,616
JardianceEmpagliflozin43$37,380
Repatha SureclickEvolocumab35$19,177
Sildenafil Citrate36$3,485
Potassium Chloride135$2,166
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$2,136
Torsemide123$2,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan$1,285$7,031,701505 claims
BayerAdempas$8,353$1,241,81590 claims
NovartisEntresto$26$55,61662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →